- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00749515
Pilot Study for Patients With Poor Response to Deferasirox
Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)
This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron overload.
The hypothesis is that patients with poor responses have physiologic barriers to deferasirox that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or genetic factors.
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of this trial is to examine three potential mechanisms of inadequate response to Exjade® in patients with transfusion dependent iron overload including patients with thalassemia syndromes, sickle cell disease and bone marrow failure.
Hypothesis: Patients have physiologic barriers to adequately respond to deferasirox that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or genetic factors.
Study objectives Primary objective
- To evaluate three potential mechanisms for inadequate response to deferasirox in a small cohort of patients with hemoglobinopathies.
- Oral pharmacokinetics measured with Cmax and AUC following standard dose deferasirox.
- Hepatobiliary excretory function
- Accessibility of chelatable iron pool by deferoxamine challenge Secondary objective(s)
- To identify risk factors that can predict adequate response including demographics, disease status, presence and severity of liver disease, trough levels of deferasirox at outpatient visits and pharmacogenomics.
- To investigate usefulness of potential surrogate measures of response including serum deferasirox levels, Hepatobiliary Iminodiacetic Acid (HIDA)nuclear medicine scan to evaluate hepatic excretory function and urinary iron excretion by deferoxamine challenge.
This is an investigator-initiated, pilot-scale, open-label physiological assessment of patients who respond poorly to deferasirox compared with patients who respond well. We plan to study 2 groups of patients: a)10 patients who have demonstrated poor responses and b) 5 control patients with good responses as defined further in the protocol. The study has two parts.
Part I: Both groups of patients will have inpatient physiological assessments with a dose of 35mg/kg of deferasirox.
Part II: Inadequate responders eligible to continue on deferasirox will continue on a dose of 35 mg/kg for three months during which time serial pharmacokinetic levels will be studied. The control patients will resume their previous clinically appropriate dosing (likely less than 35 mg/kg) and for three months have serial pharmacokinetic levels drawn as well.
The study will begin with an outpatient screening visit when demographics and historical information as well as a physical examination will be obtained and reviewed for eligibility. At that visit patients will be able to sign informed consent. Shortly thereafter patients will be admitted to the GCRC at Children's Hospital Boston for part I of the study, a 2-3 day stay during which PK and nuclear medicine studies will be performed as well as the deferoxamine urinary iron excretion challenge. Patients who are eligible will continue on to part II of the study, and for 3 months and will be monitored for compliance, PK and ferritin changes on appropriate deferasirox doses.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Part I: Inclusion criteria for Inadequate responders
- Male or female patients with transfusion dependent iron overload including patients with thalassemia syndromes, sickle cell disease and bone marrow failure.
- Patients currently on Desferal (desferrioxamine) therapy will require a one day wash out prior to the first dose of study drug.
- Dose of deferasirox: >30 mg/kg/day of deferasirox for at least 3 months
- No improvement or worsening of liver iron content (LIC) if this has been evaluated on deferasirox in the 3 months preceding the baseline studies.
- Age greater than 6 years
- Serum Ferritin: Ferritin >1500 ng/ml and rising over three month period while on deferasirox.
- Patients had to achieve 'failure' as described above previously and may or may not currently be on deferasirox and may currently be having adequate responses on doses greater than or equal to 35 mg/kg/day of deferasirox.
- Life expectancy ≥ 6 months
- Written informed consent by the patient or for pediatric patients consent of the patient's legal guardian. The definition of the term 'pediatric' for enrollment and study conduct will be in accordance with Children's Hospital IRB. Parents or the legal guardians will be fully informed by the investigator as to the requirements of the study. Pediatric patients themselves will be informed according to their capabilities in a language and in terms that they are able to understand. Written informed consent will be obtained from their legal guardian on the patient's behalf in accordance with national legislation. If capable, all patients should also personally sign their written informed consent.
Part I: Inclusion criteria for good responders:
- Male or female patients with transfusion dependent iron overload including patients with thalassemia syndromes, sickle cell disease and bone marrow failure.
- Patients currently on Desferal (desferrioxamine) therapy will require a one day wash out prior to the first dose of study drug.
- Serum ferritin less than or equal to 1000 ng/ml or declining over a 3 month period on a dose of less than 30 mg/kg of deferasirox.
- Age greater than 6 years
- Life expectancy ≥ 6 months
- Written informed consent by the patient or for pediatric patients consent of the patient's legal guardian. The definition of the term 'pediatric' for enrollment and study conduct will be in accordance with Children's Hospital IRB. Parents or the legal guardians will be fully informed by the investigator as to the requirements of the study. Pediatric patients themselves will be informed according to their capabilities in a language and in terms that they are able to understand. Written informed consent will be obtained from their legal guardian on the patient's behalf in accordance with national legislation. If capable, all patients should also personally sign their written informed consent.
Exclusion criteria for Part I:
- Pregnancy (as documented in required screening laboratory test) or breast feeding
- History of non-compliance to medical regimens or patients who are considered potentially unreliable and/or not cooperative
- Patients with transfusion requirements equal to or more frequent than every three weeks.
- AST or ALT > 400 U/L during screening
- Patients with uncontrolled systemic hypertension
- Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease not controlled by standard medical therapy
- Patients who received treatment with systemic investigational drug within the past 4 weeks or topical investigational drug within the past 7 days or are planning to receive other investigational drugs while participating in the study
- Allergy to deferoxamine
- Known contraindication to having a nuclear medicine study
- Any other condition which in the opinion of the investigator would prevent completion of the trial.
- Prior possible toxicity is not an exclusion criteria for Part I because patients require a chelating agent of which there are only two Patients who are found to be ineligible after screening procedures will have this documented on the screening log. No further data will be collected in the CRF for these patients.
Exclusion criteria for Part II:
- Patients with unacceptable toxicity to deferasirox such as renal failure or worsening cardiac function
- Patients who have failed to achieve negative iron balance at the maximum tolerated dose of deferasirox
- Patients who require an alternative chelator for specific reasons
- Patients who are currently enrolled on conflicting therapeutic trials
- Patients with serum ferritin less than 500 ng/ml at screening
- Any other condition which in the opinion of the investigator would prevent completion of the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
All patients received the same interventions of deferoxamine challenge, deferasirox dose with pharmacokinetic monitoring and HIDA scan.
Then we compared responses between patients who were known to be slow responders to deferasirox and those who were known to be rapid responders (chelated well).
|
After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
Other Names:
After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
Other Names:
All patients had a HIDA scan to assess physiologic liver clearance capacity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve of Deferasirox After a Dose of 35 mg/kg
Time Frame: 0, 1, 2, 4, 6, 8, 12, and 24 hours post dose
|
Area Under the Curve (AUC) 0 to 24 hours post dose
|
0, 1, 2, 4, 6, 8, 12, and 24 hours post dose
|
Half-Life of Deferasirox
Time Frame: 0, 1, 2, 4, 6, 8, 12, and 24 hours post dose.
|
All patients received the same interventions of deferoxamine challenge, deferasirox dose with pharmacokinetic monitoring. Then we compared responses between patients who were known to be slow responders to deferasirox and those who were known to be rapid responders (chelated well). Deferoxamine: After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption. |
0, 1, 2, 4, 6, 8, 12, and 24 hours post dose.
|
Volume of Distribution/Bioavailability of Deferasirox After a Dose of 35 mg/kg
Time Frame: 0, 1, 2, 4, 6, 8, 12, and 24 hours post dose
|
Volume of distribution/bioavailability (Vd/F)
|
0, 1, 2, 4, 6, 8, 12, and 24 hours post dose
|
Volume of Distribution/Bioavailability of Deferasirox After a Dose of 35 mg/kg
Time Frame: 0, 1, 2, 4, 6, 8, 12, and 24 hours post dose
|
Volume of distribution/bioavailability (Vd/F), adjusted per kilogram body weight
|
0, 1, 2, 4, 6, 8, 12, and 24 hours post dose
|
Clearance/Bioavailability of Deferasirox in Patients With Poor Response to Deferasirox Compared to Patients With Good Response After a Dose of 35 mg/kg
Time Frame: 0, 1, 2, 4, 6, 8, 12, and 24 hours post dose.
|
Clearance/bioavailability (CL/F)
|
0, 1, 2, 4, 6, 8, 12, and 24 hours post dose.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Polymorphisms in Genes Known to be, or Potentially Involved, in Deferasirox Disposition
Time Frame: 3 months
|
Polymorphisms in genes known to be, or potentially involved, in deferasirox disposition: UGT1a1 (including the Gilbert syndrome promoter polymorphism, (TA)nTAA),UGT1a3, BRCP/ABCG2, MRP2/ABCC2.
These genes were chosen because deferasirox is primarily eliminated by glucuronidation and subsequent biliary excretion.
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Deborah Chirnomas, MD, Boston Children's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Iron Metabolism Disorders
- Metabolism, Inborn Errors
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Metal Metabolism, Inborn Errors
- Iron Overload
- Anemia, Sickle Cell
- Thalassemia
- beta-Thalassemia
- Hemochromatosis
- Hemosiderosis
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Siderophores
- Deferasirox
- Deferoxamine
Other Study ID Numbers
- 07090349
- NIH/NHLBI 1 K12 HL087164-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Deferoxamine
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic SyndromeUnited States
-
Brigham and Women's HospitalDr. Jeffrey Thomas Stroke Shield FoundationTerminatedSubarachnoid HemorrhageUnited States
-
Beth Israel Deaconess Medical CenterMedical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaboratorsCompletedIntracerebral HemorrhageUnited States, Canada
-
Novartis PharmaceuticalsCompletedTransfusional Hemosiderosis | Transfusional Iron OverloadTaiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
-
Memorial Sloan Kettering Cancer CenterCenter for Experimental Therapeutics; F.M. KIRBY FOUNDATIONRecruitingLeptomeningeal MetastasesUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Iron Overload | Hemoglobinopathies | Thalassemia | Beta-Thalassemia | Hemochromatosis | Anemia (Iron-Loading)
-
Capital Medical UniversityPeking University First Hospital; Peking University People's Hospital; Beijing... and other collaboratorsUnknownIntracerebral HemorrhageChina
-
Beth Israel Deaconess Medical CenterMedical University of South Carolina; Massachusetts General Hospital; National... and other collaboratorsCompletedIntracerebral HemorrhageUnited States
-
Elliott VichinskyCompletedIron Overload | ThalassemiaUnited States
-
TauTona GroupWithdrawnSickle Cell Disease | Chronic Cutaneous UlcerUnited States